Vertex(US:VRTX)2025-05-05 20:32Financial Performance & Guidance - Vertex reported Q1 2025 total revenue of $2.77 billion, compared to $2.69 billion in Q1 2024[56] - The company raised the low end of its 2025 total revenue guidance to $11.85-$12.0 billion[11] - Q1 2025 non-GAAP operating income was $1.18 billion, with a non-GAAP operating margin of 43%[56] - Q1 2025 non-GAAP net income was $1.05 billion, or $4.06 per share diluted[56] Key Product Updates & Pipeline Progress - ALYFTREK was approved in the U S and U K for CF patients ages 6+, with a strong U S launch and $54 million in revenue in Q1 2025[11, 56] - JOURNAVX, approved in the U S for acute pain, saw strong early uptake with over 20,000 prescriptions filled through April 18th[11, 55] - CASGEVY launch is gathering momentum across all regions, with $14 million in revenue in Q1 2025[11, 56] - The pivotal trial for Zimislecel in T1D is expected to complete enrollment and dosing in Q2 2025, with potential global regulatory submissions in 2026 targeting ~60,000 severe T1D patients in the U S and Europe[11, 17] - Enrollment is complete in the interim analysis cohort for Povetacicept in IgAN, with potential for U S accelerated approval in H1 2026[11, 32] - VX-407 for ADPKD is advancing to Phase 2 in H2 2025, targeting up to ~30,000 patients with a subset of variants in the PKD1 gene[11, 39]